Patient P-03460
Therapy response
Improving
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
88%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S11
- Day 56 SC-12 recommended — Supportive Compound SC-12
- Day 57 Patient accepted — Started SC-12 in the companion
- Day 63 GI symptom burden −18% vs expected — Supportive Compound SC-12
- Day 64 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 69 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 64.
Primary contributors, last 14 days
- Toxicity+13
- Nutritional resilience-9
- Treatment adherence-6
- GI instability+3
- Inflammatory activity+2
What helped?
- Supportive Compound SC-12Day 56Result: symptom burden −18%
LIFE OS recommendation
GI Support Protocol GI-04
91%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 82% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 31/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 63 and rising
- WearableSleep 5.2 h, below personal baseline
- Inflammatory signalling ↑45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 60
- Drug metabolism and exposure ↑20
- BloodToxicity index 54
- Autonomic recovery ↓20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.1 · butyrate capacity 31/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 53 ms
- Sleep
- 5.8 h
- Steps
- 6,320
- Resting HR
- 67 bpm
Daily log: GI score 63, nutritional resilience 33, adherence 48.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03181 | 17% | S03 | — | — | 75 |
| P-03113 | 19% | S08 | NP-02 | no change | 73 |
| P-03023 | 17% | S16 | — | — | 73 |
| P-03266 | 17% | S05 | — | — | 73 |
| P-03349 | 19% | S11 | — | — | 71 |
| P-03346 | 20% | S17 | GI-04 | improved | 71 |
| P-03201 | 27% | S15 | GI-04 | improved | 68 |
| P-03252 | 18% | S13 | SC-12 | improved | 68 |
| P-03311 | 18% | S06 | — | — | 68 |
| P-03456 | 18% | S18 | — | — | 68 |
| P-03214 | 17% | S18 | — | — | 68 |
| P-03429 | 19% | S04 | — | — | 68 |